Investors should buy Xylem after its acquisition of fellow water technology firm Evoqua, Goldman Sachs said.
The bank reinitiated its buy rating on Xylem with a price target of $133, which implies a 24.2% upside from where the stock finished Wednesday's session.
In the deal, Lee said the company gains a portfolio of water treatment solutions and better placement in U.S. industrial end markets.
And the acquisition only "further strengthens its status as a clear ESG winner," Lee said.
Any difficulties with acquisition integration could also impact the stock, he said.
Persons:
Goldman Sachs, Evoqua, Brian Lee, Lee, — CNBC's Michael Bloom
Locations:
North America